- Saint Petersburg, Russia
- Minority stake
Solopharm is a producer of pharmaceuticals, with focus on liquid drugs production. Product portfolio of Solopharm includes infusions, injectables, and a number of emerging branded products — ophthalmological drugs, nasal forms. All the drugs are generic drugs. Products are sold both to Russian hospitals and to pharmacies. The Company operates modern production facility located in Saint-Petersburg.
The company’s growth rate is reported at 78% in USD, up to $232M, and 91%* in Rubles, up to 7.1B Rubles.
"After coming off of a benchmark year for The OZON Group, 2012 began with the pivotal acquisition of Sapato.ru which has strengthened the already fortified leadership of OZON in the marketplace," said Maelle Gavet, CEO of OZON Holdings. "Efforts for the past six months have been concentrated on furthering the growth of OZON as a whole while blending Sapato.ru and OZON.ru to band together seamlessly. It has been a very organic and prolific progression."
Baring Vostok Private Equity Fund IV invested 50 million dollars to support further growth of Tinkoff Credit Systems (TCS).